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Abstract
■ Choosing between sooner smaller rewards and larger later
rewards is a common choice problem, and studies widely agree
that frontostriatal circuits heavily innervated by dopamine are
centrally involved. Understanding how dopamine modulates
intertemporal choice has important implications for neuro-
biological models and for understanding the mechanisms under-
lying maladaptive decision-making. However, the specific role of
dopamine in intertemporal decisions is not well understood.
Dopamine may play a role in multiple aspects of intertemporal
choices—the valuation of choice outcomes and sensitivity to
reward delays. To assess the role of dopamine in intertemporal
decisions, we tested Parkinson’s disease patients who suffer from
dopamine depletion in the striatum, in either high (on medica-
tion, PDON) or low (off medication, PDOFF) dopaminergic states.
Compared with both PDOFF and healthy controls, PDON made
more farsighted choices and reduced their valuations less as a
function of increasing time to reward. Furthermore, reduced dis-
counting in the high dopaminergic state was robust across multi-
ple measures, providing new evidence for dopamine’s role in
making decisions about the future. ■
INTRODUCTION
Intertemporal decisions—choices between sooner smaller
and larger later rewards—are ubiquitous. Studies widely
agree that the striatum as well as the pFC (particularly
the ventromedial and the lateral pFC) are centrally in-
volved in intertemporal choice (Figner et al., 2010; Kable
& Glimcher, 2007, 2010; Pine, Shiner, Seymour, & Dolan,
2010; McClure, Laibson, Loewenstein, & Cohen, 2004).
Notably, these frontostriatal circuits are heavily inner-
vated by dopamine (Dagher & Robbins, 2009; Dalley,
Mar, Economidou, & Robbins, 2008). Understanding how
dopamine modulates intertemporal choice has important
implications for neurobiological models of this process, as
well as for understanding the mechanisms underlying
maladaptive decision-making (such as occurs in addic-
tion). However, the specific role of dopamine in inter-
temporal decisions is not well understood.
Pharmacological manipulations allow insight into the
causal role of dopamine in intertemporal decisions. One
approach to studying the role of dopamine in decision-
making is to use Parkinson’s disease as a model system.
In its early stages, Parkinson’s disease involves degenera-
tion of dopaminergic inputs mainly to the striatum, pro-
viding a test of the importance of striatal dopamine in
decision-making. Importantly, because Parkinson’s disease
is treated with dopamine replacement therapy, which can
be withheld for a short period of time, patients can be
tested in either high or low dopaminergic states, allowing
assessment of the effects of dopamine while keeping
more general disease-related factors constant.
Existing pharmacological studies have yielded complex
and inconsistent results. In healthy, young adults, dopa-
mine precursor administration (L-dopa) led to more short-
sighted choices in one study (Pine et al., 2010), whereas
selectively increasing pFC dopamine led to more far-
sighted choices in another study (Kayser, Allen, Navarro-
Cebrian, Mitchell, & Fields, 2012), possibly because of
different roles of striatal versus pFC dopamine. In con-
trast, studies of Parkinson’s disease patients (without
impulse control problems) found no effects of dopami-
nergic state (Simioni, Dagher, & Fellows, 2012; Milenkova
et al., 2011).
One source of such inconsistencies could be that pre-
vious studies used task paradigms that differed in their
sensitivity. Investigations of intertemporal decision-
making have typically used a single metric of discount-
ing derived from pairwise choices between sooner and
later rewards. Here we used two tasks that are com-
monly used to assess pairwise intertemporal choices, a
binary choice task and a choice titration task, and a task
requiring valuations of single choice options. Additionally,
we used an analysis approach that allowed us to sepa-
rately assess the influence of reward magnitude and re-
ward delay. We compared early-stage Parkinson’s disease
patients—either on or off dopaminergic medication—to
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a healthy control group. This allowed us to investigate how
intertemporal decision-making is affected by (i) striatal
dysfunction in general, comparing Parkinson’s disease
patients to controls, or (ii) changes in dopamine levels,




Thirty-three participants with a diagnosis of idiopathic
Parkinson’s disease were recruited from the Center for
Parkinson’s Disease and Other Movement Disorders at
Columbia University Medical Center. Only patients in early
stages of disease (Hoehn-Yahr Stages 1–3), when the
striatum is the primary site of dopaminergic dysfunction
(Cools, 2006; Hornykiewicz, 1989; Kish, Shannak, &
Hornykiewicz, 1988; Bernheimer, Birkmayer, Hornykiewicz,
Jellinger, & Seitelberger, 1973), were recruited. Patients
were randomly assigned to be tested either on medication
(PDON; n= 16) or off medication (PDOFF; n= 17). Twenty
healthy controls, matched to Parkinson’s disease patients
on age and education (see Table 1), were recruited
from the community surrounding Columbia University.
All participants provided informed consent in accor-
dance with the guidelines of the Institutional Review
Board of Columbia University and were paid $12/hr
for their participation, in addition to a variable payment
based on their choices (see below).
Participants were excluded if they had suffered brain
injury or were diagnosed with neurological or psychiatric
disorders other than Parkinson’s disease. Participants
completed a neuropsychological battery to assess gen-
eral cognitive functioning and were excluded if they ex-
hibited impairment, evidenced by scoring 26 (2.5 SDs
below the mean) or below on the Mini Mental State
Examination (MMSE). Data from two Parkinson’s disease
participants were excluded (both tested on medication)—
one because of initially unreported brain surgery and
one because of low MMSE score, leaving 17 PDOFF and
14 PDON participants. Two age-matched controls were
excluded because of low MMSE scores, leaving 18 control
participants in the analyses.
Table 1. Demographic and Neuropsychological Characteristics of Participants
n (Male/Female)
Controls 18 (5/13) PDOFF 17 (7/10) PDON 14 (6/8)
pM SD M SD M SD
Agea,b 63.6 8.4 61.9 7.8 70.8 8.0 .004, .021
Educationa 16.1 0.7 16 2.3 17.7 2.3 .038
Digit Spana 12.1 2.0 12.7 2.0 10.8 1.5 .009
NAART 16.2 9.8 14.9 6.2 15.4 6.6 ns
COWAT 48.6 17 49.5 14.2 43.6 9.0 ns
MMSE 29.7 0.6 29.4 0.8 29.6 0.8 ns
BDIc 3.4 3.4 6 4.1 7.32 6.3 .02
BDI-Cognitive 1.1 1.1 1.7 2.4 2.1 2.3 ns
UPDRS-III – 14.5 10.2 21.2 11.3 ns
H-Y Scale – I–III I–III ns
L-dopa averaged – 387.5 231.1 513.9 302.9 ns
Agonist LEDe – 310.0 166.3 249.0 189.6 ns
Total LED – 658.7 362.3 499.7 371.0 ns
Disease duration – 7.2 5.1 7.6 6.9 ns
Demographic characteristics were compared between groups using independent sample t tests.
NAART = North American Adult Reading Test; COWAT = Controlled Oral word Association Test; BDI = Beck Depression Inventory; UPDRS =
Unified Parkinson’s disease Rating Scale; H-Y scale = Hoehn and Yahr scale.
aSignificant difference between PDOFF and PDON.
bSignificant difference between Controls and PDON.
cSignificant difference between Parkinson’s disease patients and Controls.
dNote that not all Parkinson’s disease patients are on L-dopa.
eNote that not all Parkinson’s disease patients are on agonists.
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PDON were tested within 3 hr of their last medication
dose; PDOFF were withdrawn overnight from their medi-
cations and tested at least 14 hr after their last medication
dose, following prior studies (Foerde, Braun, & Shohamy,
2013; Shohamy, Myers, Geghman, Sage, & Gluck, 2006;
Frank, Seeberger, &O’Reilly, 2004; Cools, Barker, Sahakian,
& Robbins, 2001). As is common clinical practice, most
patients were being treated with a combination of L-dopa
and dopamine agonists. PDON/PDOFF: 10/16 treated with
L-dopa alone or in combination with an agonist, 2/0 on an
agonist alone, and 2/1 on an MAOI (e.g., Rasagiline) alone;
of those treated with agonists, 4 PDON and 6 PDOFF were
treated with D2/D3 agonists (Pramipexole, Ropinirole).
In addition 3 PDON and 5 PDOFF were on antidepressant
or antianxiety medication. The total daily L-dopa equiva-
lent dosage (LED) was calculated for each participant
according to Tomlinson et al. (2010; Table 1). Precise
medication dosage information could not be obtained
from 1 PDON and 1 PDOFF, and LED was not calculated
for these participants.
Comparison of PDON and PDOFF groups revealed that
the groups did not differ in disease duration or severity
(see Table 1). There were, however, differences in age,
education, and total digit span (a measure of working
memory), with PDON being older, more educated, and
having lower digit spans than PDOFF. To investigate
whether any of the results reported below might be due
to group differences on these variables, we report not
only the results of our main analyses (without covariates)
but also the results of additional analyses that included
age, education, and digit span as covariates of no interest
(because of 2 PDON missing digit span scores, the re-
spective analyses use a somewhat reduced data set).
Tasks
Participants completed three tasks: a binary intertemporal
choice task, a valuation rating task, and a choice titration
task, all of which required choices between or assess-
ments of smaller-sooner (SS) and larger-later (LL) rewards,
following Figner et al. (2010).
Participants completed all tasks twice. The two test
sessions were separated by about an hour, during which
participants completed a neuropsychological test battery
and an unrelated task. Tasks were identical across the
two administrations, except that the reward amounts
were slightly jittered by up to ±$3 to reduce memory
effects. Additionally, SS rewards in the choice tasks were
always presented on the left side of the screen in the first
task and on always on the right side of the screen in the
second task. It has been proposed that the ordering of
SS and LL choice options could influence the degree of
discounting (Weber et al., 2007). However, choice option
ordering did not affect choice patterns and was not con-
sidered further in analyses (main effect of SS/LL ordering:
p = .35; all interactions with SS/LL ordering: ps > .28).
Four PDON, 1 PDOFF, and 1 Control completed only the
first task administration; our analysis approach (see
below) allowed us to keep these participants’ data in the
analyses.
Binary Choice Task
The first task in each of the two test sessions was the
binary choice task. Binary choice tasks are commonly
used in intertemporal choice research. However, the task
used in this study assessed not only overt choices but
also sensitivity to changes in relative amount differences,
time differences, and immediacy, potentially shedding
additional light on the mechanisms underlying differ-
ences in overt choices. In each of 36 choice trials per task
administration (i.e., 72 total trials), participants chose be-
tween an SS and an LL option (Figure 1A). Across trials,
the following factors were varied factorially: (i) the Relative
Difference between rewards (the LL was either 0.5%, 1%,
10%, 15%, 20%, 25%, 30%, 50%, or 75% larger than the
Figure 1. Task schematic. Participants completed three intertemporal decision tasks. (A) Binary choice task trial: Participants used a computer
mouse to select the sooner smaller or larger later reward. (B) Valuation rating task trial: Participants used a computer mouse to rate the attractiveness
of various monetary options on a visual analog scale. (C) Choice titration task trial: For each row, participants selected whether they preferred
the sooner smaller or larger later reward.
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SS); (ii) the Time Difference between SS and LL (time of
delivery of the LL was either 2 or 4 weeks later than time
of delivery of the SS); (iii) the SS was either an immediate
reward (available today: “now trial”) or a future reward
(available in 2 weeks: “not-now” trial) (Now/Not-now).
Additionally, but not part of the factorial variation and
not of theoretical interest here, (iv) the SS amounts
differed across trials (Outcome magnitude), as SS
amounts were (pseudo)randomly drawn when design-
ing the task (see Figner et al., 2010; McClure et al.,
2004, from which the binary choice task was originally
developed). In total, the presented amounts varied be-
tween $15 and $84.50 (across both SS and LL outcomes).
Participants used a mouse to select their preferred option
and clicked a “Next” button to proceed to the following
trial (Figure 1A). One PDON and 2 PDOFF required some
assistance-making responses; they pointed to their answer
on the computer screen, and the experimenter handled
the mouse.
Valuation Rating Task
After the choice task, participants completed a valuation
task that assessed the subjective value of outcomes as a
function of reward magnitude (Outcome magnitude)
and time of delivery (Time) through explicit rating judg-
ments in a nonchoice valuation context (Figure 1B). In
each valuation task, participants rated 12 single options
(i.e., 24 total ratings), one at a time, for their attractive-
ness. The options were from the Choice Task and re-
flected the four time points used in the Choice Task
(“Today,” “2 weeks,” “4 weeks,” and “6 weeks”) crossed
with low (approx. $30), medium (approx. $45), and high
(approx. $60) reward magnitudes (the amounts were jit-
tered somewhat around these approximate numbers).
Participants rated each option on a continuous visual
analog scale with the endpoints “Very unattractive” (spec-
ified as “$20 in 6 weeks”) and “Very attractive” (specified
as “$80 today”).
Choice Titration Task
Next, participants completed two “titrator” trials per task
(i.e., 4 “titrators” total) in which they made a series of
binary choices between a constant SS reward and a step-
wise changing LL reward, presented in a table-like format
(Figure 1C). On the first titrator trial, participants chose
between an SS reward of $50 today and an LL reward
ranging from $55 to $105 in $5 increments delivered in
3 months (“Now” titrator). On the second titrator trial,
participants chose between an SS reward of $30 delivered
in 2 months and an LL reward ranging from $35 to $85
in $5 increments delivered after 5 months (“Not now”
titrator). The choice titration task allowed participants
to indicate in a very simple format their indifference point
between the SS and LL outcome.
All trials across all phases of the experiment were self-
paced to eliminate time pressure related to motor diffi-
culty in the Parkinson’s disease patients.
Participants were instructed that one trial would be
randomly selected at the end of the experimental ses-
sion and the choice on that trial paid out: If a trial with
an immediate reward choice was selected, the amount
was paid in cash at the end of the testing session; if a
delayed reward trial was selected, the amount was sent
to participants by mail 3 days before the specified time
of delivery.
Analysis
Binary choice data were analyzed with generalized mixed-
effects models using the glmer function of the lme4 pack-
age (version 1.1-7) in R (Bates, Maechler, Bolker, & Walker,
2014). The repeated-measures nature of the data was
taken into account by including a per-participant ran-
dom intercept and modeling all within-subject predic-
tors both as fixed effects and random slopes varying
over participant, plus all possible random correlation
terms, incorporating a “maximal” random effects struc-
ture, as recommended by Barr, Levy, Scheepers, and Tily
(2013), to avoid inflated Type 1 errors. p Values were
determined using likelihood ratio tests using the func-
tion mixed of the package afex (Singmann, 2014). As a
general strategy, we first used an omnibus model inves-
tigating Group differences between Controls, PDON, and
PDOFF. Significant Group effects (see below) and inter-
actions of Group with task factors were further investi-
gated using pairwise follow-up models (Control vs. PDON,
Control vs. PDOFF, PDON vs. PDOFF).
Valuation rating data were analyzed with an analogous
approach, except that we used Gaussian (instead of bino-
mial) mixed-effects models appropriate for the continu-
ous response measure, using the lmer function of the
lme4 package; p values were again determined using like-
lihood ratio tests.
Choice titration data were analyzed similarly to Weber
et al. (2007) but used a hyperbolic discounting model.
The discount rate k was calculated for each of the four
titrator trials based on the point at which participants
switched from the SS to the LL: For example, if a partic-
ipant preferred $50 today over $60 in 3 months but pre-
ferred $65 in 3 months over $50 today, we assumed that
their point of indifference was between $30 today and
$62.50 in 3 months, determining their discount rate k
for this titrator. Because the k values were highly inter-
nally consistent across the four titrators with a Cronbach’s
alpha of .9, we computed the average k per participant
and used this value to investigate group differences using
linear regression together with post hoc pairwise group
comparisons using the glht function from the library
multcomp (Hothorn, Bretz, & Westfall, 2008) with Tukey
contrasts and adjusted p values.
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Additional analyses then investigated whether any of
the observed Group results might be due to group differ-
ences in covariates of no interest (Age, Education, Digit
Span). Digit span scores were not obtained for 2 PDON
participants, resulting in reduced sample sizes for these
analyses.
To facilitate comparison of temporal discounting
across tasks and with previous studies, we estimated
the discount rate (k) for each task. For the binary choice
task, we estimated for each participant separately their
best-fitting k using R’s glm.fit function, predicting their
binary choices as a function of the implied discount rate
for each choice trial (i.e., if the participants had been
indifferent between the two options offered on that
trial). For the valuation rating task—as for the binary
choice and the titrator tasks—the best-fitting k was esti-
mated using Mazur’s (1987) standard one-parameter
model of hyperbolic discounting (see Figner et al., 2010).
Numerous previous studies, including those in patients
with Parkinson’s disease (Simioni et al., 2012; Milenkova
et al., 2011; Housden, O’Sullivan, Joyce, Lees, & Roiser,
2010), have assumed hyperbolic discounting. For the valu-
ation ratings, separate linear regressions were run step-
wise for a broad range of ks (ranging from −50 to 200 in
steps of 0.05) for each participant, and the k that best
explained their pattern of subjective values represented
in the valuation ratings was selected as their valuation-
implied discount rate k (based on the linear regressions’
R2 value). We also tested whether an exponential model
would be more appropriate for the valuation rating data
and found that R2 values were significantly larger for the
hyperbolic than the exponential model (Wilcoxon
signed rank test, p < .001; Mhyp = 0.64, SD = 0.21; Mexp =
0.63, SD = 0.21), whereas there was no significant dif-
ference between the two models in how well they pre-
dicted participants’ choices in the binary choice task
(Wilcoxon signed rank test, p = .105). This slight supe-
riority of the hyperbolic compared with the exponential
model is consistent with a previous study using these
tasks (Figner et al., 2010). For the choice titration task,
k was calculated as outlined above. Finally, pairwise corre-




All task factors except Now/Not-now showed clear and
significant main effects in the expected directions. LL
choice increased as the Relative Difference between
options increased (χ2(1) = 36.20, p < .001) and as Out-
come magnitude increased (χ2(1) = 55.89, p < .001, a
pattern known as the “magnitude effect” in intertemporal
choice (Thaler, 1981). LL choices decreased as Time
Difference increased, and participants had to wait longer
for the LL (χ2(1) = 29.28, p < .001). Whether the SS was
an immediate or future reward (Now/Not-now trial) did
not influence choice significantly (χ2(1) = 0.04, p =
.83). This pattern of significant main effects was observed
in all pairwise follow-up models and will not be further
reported on in detail; thus, for the remainder of the
choice analyses, we focus on Group differences.
Overall, there was a significant effect of Group (χ2(2) =
7.66, p = .02), indicating that disease and/or medication
status affected choices between sooner versus later re-
wards. Pairwise follow-up models revealed that this effect
was driven by greater preference for LL rewards in the
PDON group relative to both Controls and PDOFF (Figure 2;
PDON vs. Control: χ
2(1) = 5.65, p = .02; PDON vs. PDOFF:
χ2(1) = 6.25, p = .01). PDOFF and Controls did not differ
significantly from each other (PDOFF vs. Control: χ
2(1) =
0.1, p = .75).
Group showed significant interactions with Time Dif-
ference (χ2(2) = 7.74, p= .02) and Outcome magnitude
(χ2(2) = 8.95, p = .01), whereas interactions with Rela-
tive Difference and Now/Not-now were not significant
(χ2(2) = 1.29, p = .53; χ2(2) = 2.48, p = .29, respec-
tively). Pairwise follow-up models revealed that the sig-
nificant Time Difference interaction was due to the
Controls significantly differing from both PDON (χ
2(1) =
4.39, p = .04) and from PDOFF (χ
2(1) = 6.53, p = .01):
In Controls, increasing the Time Difference from 2 to
4 weeks led to a somewhat steeper drop in LL choices,
compared with the PDON and the PDOFF groups. PDON
and PDOFF did not differ significantly from each other in
the effect of Time Difference on choice (χ2(1) = 0.01,
Figure 2. Proportion choices of LL rewards. Proportions of
farsighted choices in the binary choice task as a function of relative
differences in reward magnitudes (averaged across participants, task
administrations, and other task factors). PDON were more likely to
choose the larger later reward than the other groups. All groups made
more farsighted choices as the relative difference between the SS and
LL reward increased.
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p= .97 (Proportion LL choices: ControlM(2weeks)= 0.40,
M(4weeks)=0.30, PDOFFM(2weeks)=0.37,M(4weeks)=
0.31, PDON M(2weeks) = 0.69, M(4weeks) = 0.61).
Thus, this result suggests that Controls may be more sen-
sitive to time information than Parkinson’s disease patients
both on and off medication. The follow-up models showed
that the significant Group difference in the magnitude
effect was due to the PDON group showing a weaker mag-
nitude effect than the other two groups (PDON vs. Control:
χ2(1) = 5.63, p = .02; PDON vs. PDOFF: χ
2(1) = 4.65, p =
.03); Controls and PDOFF did not differ significantly on
this dimension (χ2(1) = 0.16, p = .69).
When we reran the above models including the covar-
iates Age, Education, and Digit Span, the Group effect
was virtually the same as in the analysis without covari-
ates (χ2(2) = 9.03, p= .01), and none of the three covar-
iates showed a significant effect on choice (Age: χ2(1) =
0.43, p = .51; Education: χ2(1) = 2.68, p = .10; Digit
Span: χ2(1) = 0.02, p = .89).
The results of the pairwise follow-up analyses with
covariates also did not differ substantially from the
models without covariates. As two pairwise follow-up
models with covariates had to be simplified to reach
convergence due to the increased model complexity
and/or reduced sample size, we followed suggestions
by Barr et al. (2013) for simplification. As in the main
analysis, the PDON group chose the LL reward signifi-
cantly more often relative to both Controls and PDOFF
(PDON vs. Control: χ
2(1) = 6.39, p = .01; PDON vs.
PDOFF: χ
2(1) = 7.74, p = .005). PDOFF and Controls
did not again differ significantly from each other (PDOFF
vs. Control: χ2(1) = 0.08, p = .78). All other results re-
mained qualitatively the same as well, with the exception
that the interactions between PDON versus Controls and
(i) Time Difference and (ii) Outcome magnitude only
approached significance in the models with covariates
(Time Difference: χ2(1) = 2.65, p = .10; Outcome mag-
nitude: χ2(1) = 2.87, p = .09). Thus, we cannot rule out
that these latter two Group differences were partly due
to group differences in the covariates (alternatively the
reduced sample size and/or increased model complexity
might explain the differences in p values).
Valuation Ratings
The valuation task assessed the subjective value of re-
ward magnitude (Outcome magnitude) and time of de-
livery (Time) through explicit rating judgments of the
attractiveness of single options presented in a nonchoice
context (Figure 1B).
As for the binary choice data, there were significant
main effects of Outcome magnitude and Time in the ex-
pected directions, with higher Outcome magnitude and
earlier time of delivery leading to higher attractiveness
ratings (Outcome magnitude: χ2(1) = 85.41, p < .001;
Time: χ2(1) = 63.63, p < .001; Figure 3). Although there
was no significant main effect of Group in the overall
option valuation ratings (χ2(2) = 3.90, p = .14) suggest-
ing no overall Group differences in perceived attractive-
ness of the rewards, there was a significant interaction
between Group and Time (χ2(2) = 13.24, p = .001):
Pairwise follow-up models revealed that the interaction
was due to the PDON group being significantly less sensi-
tive to increasing time (see Figure 3A) compared with
both PDOFF (χ
2(1) = 5.64, p = .02) and Controls (χ2(1) =
15.39, p< .001); that is, attractiveness declined less steeply
with increasing time of delivery in PDON compared with
the other two groups. PDOFF and Controls did not differ
significantly in their Time effect (χ2(1) = 1.58, p = .21).
Additionally, pairwise follow-up models revealed that,
although the main effect of Group was not significant,
the PDOFF Group differed marginally significantly from
the other groups in that they exhibited overall lower
valuations (PDON vs. PDOFF: χ
2(1) = 3.26, p = .07; PDOFF
vs. Controls: χ2(1) = 3.26, p = .07). PDON and Controls
did not differ from each other (χ2(1) = 0.23, p = .63).
To investigate whether the results might be due to
group differences in Age, Education, or Digit Span, we ran
the main model with these covariates added. Consistent
with the choice analysis, none of the covariates showed
Figure 3. Valuation ratings. (A) Valuation ratings as a function of Group and Time of Delivery (averaged across participants, task administrations,
and other task factors). (B–D) Valuation ratings as a function of Time of Delivery and Amount Level (averaged across participants and task
administrations), shown separately for Controls (B), PDOFF (C), and PDON (D).
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a significant main effect (Age: χ2(1) = 1.54, p = .21;
Education: χ2(1) = 0.003, p = .96; Digit Span: χ2(1) =
2.01, p = .16). The Group effect remained nonsignificant
(χ2(2) = 3.81, p = .15), and the effects of Time and Out-
come magnitude as well the interaction between Group
and Time were still significant (Amount: χ2(1) = 83.90,
p < .001; Time: χ2(1) = 59.89, p < .001; Group × Time:
χ2(2) = 11.42, p = .003). Given these virtually identical
results, we did not compute the pairwise follow-ups with
covariates.
Taken together, these valuation results suggest that
dopaminergic status affected time sensitivity in valua-
tions. In particular, the PDON group reduced their valua-
tions less than did the Control and PDOFF groups as time
to reward increased (Figure 3A suggests that this was the
case particularly beyond 2 weeks). The results observed
for valuation ratings are consistent with those observed
for PDON in the binary choices and could suggest that a
decreased sensitivity to delays may contribute to more
farsighted behavior in PDON.
Choice Titration
PDON differed significantly from controls (t = 2.47, p =
.045), whereas no other groups differed significantly
(PDON vs. PDOFF: t = 1.68, p = .22; PDOFF vs. Control,
t = 0.81, p = .70). Thus, the choice titration results were
consistent with the main results observed across multiple
binary choices described above, that PDON showed a
greater preference for LL rewards.
Discount Rate (k)
Previous studies of intertemporal decision-making have
primarily focused on a single outcome measure—the dis-
count rate k. To allow comparison with previous studies,
we report the estimated mean discount rates for each
group on each task in Table 2. Importantly, the same pat-
tern of results seen in the previous analyses is observed
when considering k as the outcome measure (Table 2).
However, caution is warranted when comparing absolute
values of k across studies. The particular value of k
obtained is not likely to be meaningful, as various task
factors may influence the discount rate. For example,
whether one considers reward receipt in an acceleration
or delay framework significantly alters discounting (Weber
et al., 2007). Nonetheless, when we assessed the consis-
tency of discount rates across tasks, by computing pair-
wise correlations between the discount rates (k) for
each task, we found that k was significantly correlated
across all tasks, regardless of variation in mean k (see
Figure 4). In the valuation rating task, two participants
had extreme estimated k values (>2.5 SD above mean).
However, we obtained the same results when we excluded
these outliers from the correlation analyses (Choice titra-
tion k×Valuation rating k: r= .32, p= .028; Binary choice
k × Valuation rating k: r = .51, p = .0003), or when we
used Spearman’s rank-order correlation (Choice titration
k × Valuation rating k: rho = .42, p = .003; Binary choice
k × Valuation rating k: rho = .52, p = .0001; Binary
choice k × Choice titration k: rho = .81, p < .0001).
Furthermore, k values were also correlated with the
proportion later choices in the binary choice task (Choice
titration k × Proportion LL choices: r = −.76, p < .0001;
Valuation rating k × Proportion LL choices: r = −.41,
Table 2. Mean (SD) Discount Rate (k) across Tasks and Groups
Task
Controls PDOFF PDON
M SD M SD M SD
Binary choice 0.041 0.037 0.043 0.040 0.011 0.018
Valuation rating 0.051 0.084 0.037 0.060 0.021 0.028
Choice titration 0.008 0.005 0.007 0.004 0.004 0.004
Figure 4. Discount rates (k) across intertemporal decision-making tasks. The discount rates (k) were estimated for the binary choice task, the
valuation ratings task, and the choice titration task. Discount rates were correlated between all three tasks: (A) Choice titration k × Binary choice k,
(B) Choice titration k × Valuation rating k, and (C) Binary choice k × Valuation rating k.
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p = .0042; negative correlations are expected as higher
proportions of later choices should be associated with
lower discount rates k). As seen in Figure 4, the cor-
relations were highest between the binary choice and
titration choice tasks and lowest with the valuation rat-
ings task. This is not surprising given the similarity be-
tween the binary choice and choice titration tasks—
simultaneous presentation of two choice outcomes
with discrete values, whereas the valuation rating task
presents a single outcome and responses are made on
a continuous rating scale.
DISCUSSION
We found that modulation of dopamine levels in Parkinson’s
disease patients affected intertemporal decision-making.
Compared with both patients off medication and healthy
controls, Parkinson’s disease patients on dopaminergic
medication exhibited greater farsightedness in their
choices. This pattern of behavior was apparent both in
greater likelihood of choosing LL rewards in binary choices
between SS and LL rewards and in reduced discounting of
LL rewards, as assessed via the valuation ratings of single
outcomes. In particular, Parkinson’s disease patients on
dopaminergic medication showed decreased sensitivity
to increasing delays to rewards. Patients withdrawn from
dopaminergic medication showed a trend toward reduced
valuation of single outcomes but did not differ signifi-
cantly in their binary choices from healthy controls. Addi-
tionally, individual discount rates were correlated across
all three measures of intertemporal decisions. In sum-
mary, these results implicate dopamine across multiple
methods for querying intertemporal choice preferences.
Locus of Dopamine Effects
Our results clearly suggest that loss of striatal dopamine
per se—the central feature of Parkinson’s disease in its
early to moderate stages—does not affect intertemporal
decision-making uniformly. Rather, differences in dopa-
mine levels as a function of being on versus off dopami-
nergic medication impacted choice behavior. Dopamine
is necessary for functioning of both the striatum and pFC,
regions known to be involved in intertemporal decisions
(for a review, see Carter, Meyer, & Huettel, 2010). Open
questions remain regarding the specific role of each region:
By one account, the striatum is particularly engaged when
rewards are available immediately, whereas pFC is engaged
regardless of delay and particularly when decisions are
more difficult (McClure et al., 2004). Another account has
the striatum and medial pFC representing the subjective
value of rewards regardless of delay and their immediacy
(Kable & Glimcher, 2007, 2010). Although the striatum
may respond preferentially to immediate rewards, it may
additionally be more responsive to delayed rewards with
increasing age (Samanez-Larkin et al., 2011). Our results
are compatible with both points of view and, together with
prior work showing increased impulsivity in young adults
administered L-dopa (Pine et al., 2010), suggest that in-
creasing dopamine levels in the striatum may affect
young and old adults differentially, with greater benefits
for farsighted choice in older adults (as found in the
current study).
Previous work has causally implicated the lateral pFC
in farsighted decisions (Figner et al., 2010), and pFC
dopamine levels may influence baseline activity levels
underlying individual differences in intertemporal choice
(Gianotti, Figner, Ebstein, & Knoch, 2012). It is tempting
to speculate that dopaminergic modulation of the lateral
pFC could have played a role in biasing the choices of
Parkinson’s disease patients on medication toward far-
sightedness, consistent with results reporting increased
patience because of selective increases in pFC dopamine
(Kayser et al., 2012). Because pFC receives dopaminergic
projections from the ventral tegmental area, which is not
severely affected in the early stages of Parkinson’s disease
(relative to the substantia nigra), it is possible that dopa-
minergic medication enhances dopamine levels in pFC in
Parkinson’s disease patients to an extent that results in
farsightedness even beyond that of healthy controls.
Finally, connectivity between striatum and pFC may
be relevant. Stronger structural and functional connec-
tivity between striatum and lateral pFC has been linked
to greater patience across individuals (Van den Bos,
Rodriguez, Schweitzer, & McClure, 2014), and functional
connectivity is influenced by dopamine: Pharmacologically
increasing dopamine in pFC affects connectivity with the
striatum in intertemporal choice (Kayser et al., 2012),
and functional connectivity between striatum and lateral
pFC during rest is enhanced by L-dopa relative to placebo
(Kelly et al., 2009). Thus, enhanced connectivity through
dopaminergic medication could also contribute to the
results we report here.
Dopamine and Consideration of Future Events
Studies investigating the link between dopamine and
consideration of future events in decision-making have
yielded mixed results. Our results are consistent with
findings in many pharmacological studies that increasing
dopamine levels leads to more patient choices, whereas
decreasing dopamine levels leads to decreases in choice
of delayed rewards or willingness to exert effort for larger
rewards (Kayser et al., 2012; Salamone & Correa, 2012;
Floresco, Tse, & Ghods-Sharifi, 2008; Bizot et al., 2007;
Salamone, Correa, Farrar, & Mingote, 2007; van Gaalen,
van Koten, Schoffelmeer, & Vanderschuren, 2006; Pietras,
Cherek, Lane, Tcheremissine, & Steinberg, 2003; de Wit,
Enggasser, & Richards, 2002; Cardinal, Robbins, & Everitt,
2000; Wade, de Wit, & Richards, 2000; Richards, Sabol, &
de Wit, 1999). In particular, a recent study showed
that administration of methylphenidate, which increases
extracellular levels of dopamine in the BG and pFC,
decreased temporal discounting in nonhuman primates
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(Rajala, Jenison, & Populin, 2015). However, other studies
have found that increases in dopamine lead to decreases
in patient choices (Pine et al., 2010; Evenden & Ryan,
1996; Logue et al., 1992) or to no differences (Acheson
& de Wit, 2008; Hamidovic, Kang, & de Wit, 2008). These
findings may be reconciled by the idea that the relation-
ship between dopamine levels and performance on a given
task follows an inverted U-shape function (Joutsa et al.,
2015; Cools & D’Esposito, 2011) such that individual or
population level differences in baseline dopamine influ-
ence whether manipulating dopamine levels will be bene-
ficial or detrimental. Consistent with this idea, some
studies found dose- or population-dependent effects
(Floresco et al., 2008; Bizot et al., 2007; Cardinal et al.,
2000). Such baseline differences (see also Gianotti et al.,
2012; Eisenegger et al., 2010) may explain why Pine et al.
(2010) found that L-dopa increased temporal impulsivity.
In healthy young participants, administering L-dopa may
result in overdosing of frontostriatal circuits depending
on individual differences in baseline dopamine levels
(Kayser et al., 2012; Clatworthy et al., 2009; Cools, Sheridan,
Jacobs, & D’Esposito, 2007). In this study, medication
dosage is titrated to each individual’s need, perhaps
allowing the enhanced patience often seen with moderate
increases in dopamine levels.
The current results are also broadly consistent with a
recent study investigating the role of dopamine in goal-
directed behavior. Using a two-step reward-learning task
that allowed computational dissection of habitual versus
goal-directed control, Parkinson’s disease patients on and
off L-dopa were compared in a within-subject design.
Goal-directed choices were impaired in Parkinson’s dis-
ease patients off medication, but performance was fully
restored to the level of healthy controls when Parkinson’s
patients were on medication (Sharp, Foerde, Daw, &
Shohamy, in press). Interestingly, a separate study as-
sessed the relationship between goal-directed learning
on the same two-step reward-learning task used by Sharp
et al. (in press) while also assessing intertemporal choice
in the same participants (Hunter, Shi, Soufian, Decker, &
Hartley, 2015). They found that goal-directed learning
was predictive of greater patience in intertemporal deci-
sions. Thus, dopamine may promote behaviors that in-
volve prospection in some form, as is the case for making
farsighted choices and predictions about future rewards
based on complete models of the environment, potentially
by simulating paths to future outcomes (Doll, Duncan,
Simon, Shohamy, & Daw, 2015).
Impulsivity in Parkinson’s Disease
A considerable number of studies have found that
Parkinson’s disease patients diagnosed with impulse
control disorders show signs of temporal impulsivity
and increased reward sensitivity (Voon & Dalley, 2011;
Housden et al., 2010; Voon & Fox, 2007), in particular
when treated with dopamine agonists (Voon, Mehta, &
Hallett, 2011). Only a few studies have looked at tem-
poral discounting in Parkinson’s disease patients without
impulse control disorders: Two studies found no differ-
ence between Parkinson’s disease and controls (Simioni
et al., 2012; Housden et al., 2010), and one study found
differences in discounting between Parkinson’s disease
and controls (Milenkova et al., 2011), that is, increased
impulsivity in Parkinson’s disease patients both on and
off medication. Two of the aforementioned studies made
within-subject comparisons of Parkinson’s disease patients
on and off medication, but found no effects of dopa-
minergic medication (Simioni et al., 2012; Milenkova
et al., 2011). There are several differences between stud-
ies that could have contributed to the discrepant results.
Milenkova et al. specifically assessed patients taking D2/
D3 agonists, which are associated with the development
of impulsivity in Parkinson’s disease (Dagher & Robbins,
2009), whereas only a small subset of participants in our
study were on D2/D3 agonists (see Methods section).
Another potential difference between our study and pre-
vious work is that we investigated multiple factors contrib-
uting to choices (i.e., sensitivity to delay and magnitude
of outcomes) and trial-by-trial analyses of behavior,
which may be more sensitive to differences in discounting.
Future studies should measure multiple components of
intertemporal choice while accounting for individual dif-
ferences in baseline dopamine to fully understand the
complex effects of dopamine on choice. Additionally, the
current study employed relatively small group sizes that
were not matched on age, education, and digit span. How-
ever, the inclusion of age, education, and digit span as
covariates in our analyses did not change the results, and
subsample analysis on groups matched for age and educa-
tion (not reported) also yielded results consistent with
those reported here. Thus, despite the inclusion of a rela-
tively small sample that is often characteristic of patient
studies, these additional analyses suggest that our results
are reliable.
Conclusion
Our results show that dopamine, administered in doses
that are titrated to an individual to alleviate motor symp-
toms associated with Parkinson’s disease, can enhance
farsighted choice in patients who do not suffer from im-
pulse control disorders. In particular, our results suggest
that dopamine influences sensitivity to delays when eval-
uating larger later reward outcomes. These results sug-
gest that dopamine plays a crucial role in processes
supporting intertemporal decision-making.
Acknowledgments
We are grateful to Drs. Lucien Cote, Paul Greene, and Roy Alcalay,
at the Center for Parkinson’s Disease and Other Movement
Disorders at Columbia University Medical for recruitment of
participants with Parkinson’s disease and to Nina Rouhani for
Foerde et al. 9
assistance with data collection. This work was supported by NIH-
NINDS NRSA 5F32NS063632 to K. F., NINDS R01 GG006201 to
D. S., and an NSF Career Development Award GG002716 to D. S.
Reprint requests should be sent to Karin Foerde, Department of
Psychology, New York University, 6 Washington Place, Rm 277,
New York, NY 10003, or via e-mail: karin.foerde@nyu.edu or
Bernd Figner, Behavioural Science Institute/Donders Institute for
Brain, Cognition and Behaviour, Radboud University Nijmegen,
PO Box 9104, 6500 HE Nijmegen, The Netherlands, or via e-mail:
b.figner@psych.ru.nl.
REFERENCES
Acheson, A., & de Wit, H. (2008). Bupropion improves attention
but does not affect impulsive behavior in healthy young
adults. Experimental and Clinical Psychopharmacology, 16,
113–123.
Barr, D. J., Levy, R., Scheepers, C., & Tily, H. J. (2013). Random
effects structure for confirmatory hypothesis testing: Keep it
maximal. Journal of Memory and Language, 68.
Bates, D., Maechler, M., Bolker, B., & Walker, S. (2014). lme4:
Linear mixed-effects models using Eigen and S4. R package
version 1.1-7.
Bernheimer, H., Birkmayer, W., Hornykiewicz, O., Jellinger, K.,
& Seitelberger, F. (1973). Brain dopamine and the syndromes
of Parkinson and Huntington. Clinical, morphological and
neurochemical correlations. Journal of the Neurological
Sciences, 20, 415–455.
Bizot, J. C., Chenault, N., Houze, B., Herpin, A., David, S.,
Pothion, S., et al. (2007). Methylphenidate reduces impulsive
behaviour in juvenile Wistar rats, but not in adult Wistar, SHR
and WKY rats. Psychopharmacology, 193, 215–223.
Cardinal, R. N., Robbins, T. W., & Everitt, B. J. (2000).
The effects of d-amphetamine, chlordiazepoxide,
alpha-flupenthixol and behavioural manipulations on
choice of signalled and unsignalled delayed reinforcement
in rats. Psychopharmacology, 152, 362–375.
Carter, R. M., Meyer, J. R., & Huettel, S. A. (2010). Functional
neuroimaging of intertemporal choice models. Journal of
Neuroscience, Psychology, and Economics, 3, 27–45.
Clatworthy, P. L., Lewis, S. J., Brichard, L., Hong, Y. T.,
Izquierdo, D., Clark, L., et al. (2009). Dopamine release in
dissociable striatal subregions predicts the different effects
of oral methylphenidate on reversal learning and spatial
working memory. Journal of Neuroscience, 29, 4690–4696.
Cools, R. (2006). Dopaminergic modulation of cognitive
function-implications for L-DOPA treatment in Parkinson’s
disease. Neuroscience and Biobehavioral Reviews, 30, 1–23.
Cools, R., Barker, R. A., Sahakian, B. J., & Robbins, T. W. (2001).
Enhanced or impaired cognitive function in Parkinson’s
disease as a function of dopaminergic medication and task
demands. Cerebral Cortex, 11, 1136–1143.
Cools, R., & D’Esposito, M. (2011). Inverted-U-shaped
dopamine actions on human working memory and cognitive
control. Biological Psychiatry, 69, e113–e125.
Cools, R., Sheridan, M., Jacobs, E., & D’Esposito, M. (2007).
Impulsive personality predicts dopamine-dependent changes
in frontostriatal activity during component processes of
working memory. Journal of Neuroscience, 27, 5506–5514.
Dagher, A., & Robbins, T. W. (2009). Personality, addiction,
dopamine: Insights from Parkinson’s disease. Neuron, 61,
502–510.
Dalley, J. W., Mar, A. C., Economidou, D., & Robbins, T. W.
(2008). Neurobehavioral mechanisms of impulsivity:
Fronto-striatal systems and functional neurochemistry.
Pharmacology, Biochemistry and Behavior, 90, 250–260.
de Wit, H., Enggasser, J. L., & Richards, J. B. (2002). Acute
administration of d-amphetamine decreases impulsivity
in healthy volunteers. Neuropsychopharmacology, 27,
813–825.
Doll, B. B., Duncan, K. D., Simon, D. A., Shohamy, D., & Daw,
N. D. (2015). Model-based choices involve prospective neural
activity. Nature Neuroscience, 18, 767–772.
Eisenegger, C., Knoch, D., Ebstein, R. P., Gianotti, L. R.,
Sandor, P. S., & Fehr, E. (2010). Dopamine receptor D4
polymorphism predicts the effect of L-DOPA on gambling
behavior. Biological Psychiatry, 67, 702–706.
Evenden, J. L., & Ryan, C. N. (1996). The pharmacology of
impulsive behaviour in rats: The effects of drugs on response
choice with varying delays of reinforcement.
Psychopharmacology, 128, 161–170.
Figner, B., Knoch, D., Johnson, E. J., Krosch, A. R., Lisanby,
S. H., Fehr, E., et al. (2010). Lateral prefrontal cortex and
self-control in intertemporal choice. Nature Neuroscience,
13, 538–539.
Floresco, S. B., Tse, M. T., & Ghods-Sharifi, S. (2008).
Dopaminergic and glutamatergic regulation of effort- and
delay-based decision making. Neuropsychopharmacology,
33, 1966–1979.
Foerde, K., Braun, E. K., & Shohamy, D. (2013). A trade-off
between feedback-based learning and episodic memory for
feedback events: Evidence from Parkinson’s disease.
Neurodegenerative Diseases, 11, 93–101.
Frank, M. J., Seeberger, L. C., & O’Reilly, R. C. (2004). By
carrot or by stick: Cognitive reinforcement learning in
parkinsonism. Science, 306, 1940–1943.
Gianotti, L. R., Figner, B., Ebstein, R. P., & Knoch, D. (2012).
Why some people discount more than others: Baseline
activation in the dorsal pFC mediates the link between COMT
genotype and impatient choice. Frontiers in Neuroscience,
6, 54.
Hamidovic, A., Kang, U. J., & de Wit, H. (2008). Effects of low
to moderate acute doses of pramipexole on impulsivity
and cognition in healthy volunteers. Journal of Clinical
Psychopharmacology, 28, 45–51.
Hornykiewicz, O. (1989). Ageing and neurotoxins as
causative factors in idiopathic Parkinson’s disease—A
critical analysis of the neurochemical evidence. Progress in
Neuro-Psychopharmacology & Biological Psychiatry, 13,
319–328.
Hothorn, T., Bretz, F., & Westfall, P. (2008). Simultaneous
inference in general parametric models. Biometrical Journal,
50, 346–363.
Housden, C. R., O’Sullivan, S. S., Joyce, E. M., Lees, A. J., &
Roiser, J. P. (2010). Intact reward learning but elevated
delay discounting in Parkinson’s disease patients with
impulsive-compulsive spectrum behaviors.
Neuropsychopharmacology, 35, 2155–2164.
Hunter, L. E., Shi, T. C., Soufian, Y., Decker, J. H., & Hartley,
C. A. (2015). Model-based learning predicts increased
patience in intertemporal choice. Paper presented at the
Society for Neuroeconomics, Miami, FL.
Joutsa, J., Voon, V., Johansson, J., Niemela, S., Bergman, J., &
Kaasinen, V. (2015). Dopaminergic function and
intertemporal choice. Translational Psychiatry, 5, e520.
Kable, J. W., & Glimcher, P. W. (2007). The neural correlates of
subjective value during intertemporal choice. Nature
Neuroscience, 10, 1625–1633.
Kable, J. W., & Glimcher, P. W. (2010). An “as soon as possible”
effect in human intertemporal decision making: Behavioral
evidence and neural mechanisms. Journal of
Neurophysiology, 103, 2513–2531.
Kayser, A. S., Allen, D. C., Navarro-Cebrian, A., Mitchell, J. M., &
Fields, H. L. (2012). Dopamine, corticostriatal connectivity,
10 Journal of Cognitive Neuroscience Volume X, Number Y
and intertemporal choice. Journal of Neuroscience, 32,
9402–9409.
Kelly, C., de Zubicaray, G., Di Martino, A., Copland, D. A., Reiss,
P. T., Klein, D. F., et al. (2009). L-dopa modulates functional
connectivity in striatal cognitive and motor networks: A
double-blind placebo-controlled study. Journal of
Neuroscience, 29, 7364–7378.
Kish, S. J., Shannak, K., & Hornykiewicz, O. (1988). Uneven
pattern of dopamine loss in the striatum of patients with
idiopathic Parkinson’s disease. Pathophysiologic and clinical
implications. New England Journal of Medicine, 318,
876–880.
Logue, A. W., Tobin, H., Chelonis, J. J., Wang, R. Y., Geary, N., &
Schachter, S. (1992). Cocaine decreases self-control in rats:
A preliminary report. Psychopharmacology, 109, 245–247.
Mazur, J. E. (1987). An adjusting procedure for studying delayed
reinforment. In M. L. Commons, J. E. Mazur, J. A. Nevin,
& H. Rachlin (Eds.), Quantitative analyses of behavior
(pp. 55–73). Hillsdale, NJ: Lawrence Erlbaum Associates.
McClure, S. M., Laibson, D. I., Loewenstein, G., & Cohen, J. D.
(2004). Separate neural systems value immediate and delayed
monetary rewards. Science, 306, 503–507.
Milenkova, M., Mohammadi, B., Kollewe, K., Schrader, C.,
Fellbrich, A., Wittfoth, M., et al. (2011). Intertemporal
choice in Parkinson’s disease. Movement Disorders, 26,
2004–2010.
Pietras, C. J., Cherek, D. R., Lane, S. D., Tcheremissine, O. V.,
& Steinberg, J. L. (2003). Effects of methylphenidate on
impulsive choice in adult humans. Psychopharmacology,
170, 390–398.
Pine, A., Shiner, T., Seymour, B., & Dolan, R. J. (2010).
Dopamine, time, and impulsivity in humans. Journal of
Neuroscience, 30, 8888–8896.
Rajala, A. Z., Jenison, R. L., & Populin, L. C. (2015). Decision-
making: Effects of methylphenidate on temporal discounting
in non-human primates. Journal of Neurophysiology.
Richards, J. B., Sabol, K. E., & de Wit, H. (1999). Effects of
methamphetamine on the adjusting amount procedure, a
model of impulsive behavior in rats. Psychopharmacology,
146, 432–439.
Salamone, J. D., & Correa, M. (2012). The mysterious
motivational functions of mesolimbic dopamine. Neuron,
76, 470–485.
Salamone, J. D., Correa, M., Farrar, A., & Mingote, S. M. (2007).
Effort-related functions of nucleus accumbens dopamine
and associated forebrain circuits. Psychopharmacology, 191,
461–482.
Samanez-Larkin, G. R., Mata, R., Radu, P. T., Ballard, I. C.,
Carstensen, L. L., & McClure, S. M. (2011). Age differences in
striatal delay sensitivity during intertemporal choice in
healthy adults. Frontiers in Neuroscience, 5, 126.
Sharp, M., Foerde, K., Daw, N., & Shohamy, D. (in press).
Dopamine selectively remediates “model-based” reward
learning: A computational approach. Brain.
Shohamy, D., Myers, C. E., Geghman, K. D., Sage, J., &
Gluck, M. A. (2006). L-dopa impairs learning, but spares
generalization, in Parkinson’s disease. Neuropsychologia,
44, 774–784.
Simioni, A. C., Dagher, A., & Fellows, L. K. (2012). Dissecting
the effects of disease and treatment on impulsivity in
Parkinson’s disease. Journal of the International
Neuropsychological Society, 18, 942–951.
Singmann, H. (2014). afex: Analysis of factorial experiments.
R package version 0.10-111/r111.
Thaler, R. (1981). Some empirical evidence on dynamic
inconsistency. Economic Letters, 8, 201–207.
Van den Bos, W., Rodriguez, C., Schweitzer, J. B., & McClure,
S. M. (2014). Connectivity strength of dissociable striatal
tracts predicts individual differences in temporal discounting.
Journal of Neuroscience, 34, 10298–10310.
van Gaalen, M. M., van Koten, R., Schoffelmeer, A. N., &
Vanderschuren, L. J. (2006). Critical involvement of
dopaminergic neurotransmission in impulsive decision
making. Biological Psychiatry, 60, 66–73.
Voon, V., & Dalley, J. W. (2011). Parkinson disease: Impulsive
choice—Parkinson disease and dopaminergic therapy.
Nature Reviews Neurology, 7, 541–542.
Voon, V., & Fox, S. H. (2007). Medication-related impulse
control and repetitive behaviors in Parkinson disease.
Archives of Neurology, 64, 1089–1096.
Voon, V., Mehta, A. R., & Hallett, M. (2011). Impulse control
disorders in Parkinson’s disease: Recent advances. Current
Opinion in Neurology, 24, 324–330.
Wade, T. R., de Wit, H., & Richards, J. B. (2000). Effects of
dopaminergic drugs on delayed reward as a measure of
impulsive behavior in rats. Psychopharmacology, 150, 90–101.
Weber, E. U., Johnson, E. J., Milch, K. F., Chang, H., Brodscholl,
J. C., & Goldstein, D. G. (2007). Asymmetric discounting in
intertemporal choice: A query-theory account. Psychological
Science, 18, 516–523.
Foerde et al. 11
